BioCardia, Inc. Interest Expense
BioCardia, Inc. (BCDA) reported Interest Expense of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-29.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2022-03-29
- BioCardia, Inc. interest expense for the quarter ending 2020-12-31 was $1.00K.
- BioCardia, Inc. interest expense for the quarter ending 2020-09-30 was $1.00K, a 99.11% decline year-over-year.
- BioCardia, Inc. interest expense for the quarter ending 2019-12-31 was $0.00.
- BioCardia, Inc. interest expense for the quarter ending 2019-09-30 was $112.00K.
- BioCardia, Inc. interest expense for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- BioCardia, Inc. interest expense for fiscal 2020 was $3.00K, a 97.32% decline from fiscal 2019.
- BioCardia, Inc. interest expense for fiscal 2019 was $112.00K.
- BioCardia, Inc. interest expense for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-29 | |||
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $2.00K derived: sum of 2 quarters · filed 2022-03-29 | $3.00K 10-K · filed 2022-03-29 | |
| 2020-09-30 | $1.00K 10-Q · filed 2020-11-10 | $2.00K 10-Q · filed 2020-11-10 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $112.00K derived: sum of 2 quarters · filed 2021-03-30 | $112.00K 10-K · filed 2021-03-30 | |
| 2019-09-30 | $112.00K 10-Q · filed 2020-11-10 | $112.00K 10-Q · filed 2020-11-10 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $0.00 derived: sum of 2 quarters · filed 2018-03-16 | $0.00 derived: sum of 3 quarters · filed 2018-03-16 | $0.00 10-K · filed 2018-03-16 |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 | $109.00K derived: sum of 4 quarters · filed 2019-04-02 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-14 | $0.00 10-Q · filed 2017-08-14 | $109.00K derived: sum of 3 quarters · filed 2019-04-02 | $629.00K derived: sum of 4 quarters · filed 2019-04-02 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-11 | $109.00K derived: sum of 2 quarters · filed 2019-04-02 | $629.00K derived: sum of 3 quarters · filed 2019-04-02 | $1.19M derived: sum of 4 quarters · filed 2019-04-02 |
| 2016-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-02 | $629.00K derived: sum of 2 quarters · filed 2019-04-02 | $1.19M derived: sum of 3 quarters · filed 2019-04-02 | $1.74M 10-K · filed 2019-04-02 |
| 2016-09-30 | $520.00K 10-Q · filed 2017-11-09 | $1.08M derived: sum of 2 quarters · filed 2017-11-09 | $1.63M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $557.00K 10-Q · filed 2017-08-14 | $1.11M 10-Q · filed 2017-08-14 | ||
| 2016-03-31 | $550.00K 10-Q · filed 2017-05-11 | |||
| 2015-12-31 | $1.39M 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |